Search filters

List of works by Luca Gianni

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

scientific article published on 16 February 2017

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

scientific article published on 18 July 2013

30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study

scientific article

5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.

scientific article published on 11 May 2016

A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas.

scientific article published on 7 June 2016

A phase I study of ixabepilone in combination with epirubicin in patients with metastatic breast cancer

scientific article published on 01 June 2012

A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma

scientific article published on 24 August 2018

A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer

scientific article published on 20 September 2012

A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer.

scientific article published in March 2004

AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer

scientific article published on 08 April 2013

Accurate data processing improves the reliability of Affymetrix gene expression profiles from FFPE samples

scientific article

Adjuvant trastuzumab in early breast cancer.

scientific article published on September 2006

An interview with Luca Gianni

scientific article published in January 2010

An unmet need: tailoring extended adjuvant endocrine therapy

scientific article published on 19 November 2013

Anthracycline cardiotoxicity

scientific article published on 01 January 2008

Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes

scientific article published on January 2007

Anthracycline cardiotoxicity: from bench to bedside

scientific article

Anthracyclines

scientific article published on 01 January 2002

Anthracyclines

scientific article published on 01 January 2003

Anthracyclines and early breast cancer: the end of an era?

scientific article published on 9 February 2009

Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity

scientific article (publication date: June 2004)

Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial

scientific article published on 01 February 2019

BOLERO-3 results: pharmacological activity or pharmacokinetic effect?--authors' reply

scientific article published on 01 July 2014

Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma

scientific article published on 25 January 2016

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

scientific article published on 09 February 2017

Biweekly paclitaxel and cisplatin in patients with advanced head and neck carcinoma. A phase II trial

scientific article published on 01 November 1997

Breast cancer: diagnostic and therapeutic options

scientific article published on 17 April 2004

Capecitabine/Cyclophosphamide/Methotrexate for patients with metastatic breast cancer: a dose-finding, feasibility, and efficacy study

scientific article

Cardiotoxic effects of anthracycline-taxane combinations.

scientific article

Chemotherapy in elderly patients with pancreatic cancer: Efficacy, feasibility and future perspectives

scientific article published on 29 October 2018

Clinical Development Strategies and Outcomes in First-in-Human Trials of Monoclonal Antibodies

scientific article published on 26 May 2015

Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer

scientific article published on 14 February 2012

Clinical and pharmacological phase I evaluation of ExherinTM (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumours

scientific article published on 03 February 2009

Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex

scientific article published on 01 August 2000

Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer

scientific article published in May 2004

Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?

scientific article published on 6 April 2018

Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-the Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial

scientific article published on 11 January 2018

Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.

scientific article published in January 2002

Correction: Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer

scientific article published on 01 February 2019

Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer

scientific article published on 27 September 2018

Defective one- or two-electron reduction of the anticancer anthracycline epirubicin in human heart. Relative importance of vesicular sequestration and impaired efficiency of electron addition.

scientific article published on 19 January 2006

Defective taxane stimulation of epirubicinol formation in the human heart: insight into the cardiac tolerability of epirubicin-taxane chemotherapies

scientific article published on 29 November 2006

Differences in O2 reduction by the iron complexes of adriamycin and daunomycin: the importance of the sidechain hydroxyl group

scientific article published on 01 January 1986

Direct stimulation of ERBB2 highlights a novel cytostatic signaling pathway driven by the receptor Thr701 phosphorylation

scientific article published on 09 October 2020

Dose-adjusting epirubicin in patients with altered liver function: when classical pharmacology makes good practical sense.

scientific article published in March 2003

Drugs ten years later: epirubicin.

scientific article

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

scientific article

Efficacy of ALK inhibitors on NSCLC brain metastases: A systematic review and pooled analysis of 21 studies

scientific article published on 27 July 2018

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion

scientific article published on 01 December 1994

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

scientific article published on 14 April 2014

Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer

scientific article published on 10 April 2017

Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer

scientific article published on 23 February 2015

Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy

scientific article published in December 2005

Four-drug sequential regimen in advanced breast cancer.

scientific article published on November 1987

Future options with trastuzumab for primary systemic and adjuvant therapy

scientific article published in October 2004

Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer

scientific article

HER2-directed T-cell receptor-mimicking antibody: a "Me Too" or an example of novel antitumor aggressive mimicry?

scientific article published on 8 January 2013

HER2-positive breast cancer

scientific article published on 6 December 2016

Hallmarks of triple negative breast cancer emerging at last?

scientific article

High-dose chemotherapy for breast cancer: any use for it?

scientific article published on 01 May 2002

Historical Evolution of Second-Line Therapy in Non-Small Cell Lung Cancer

scientific article published on 23 January 2017

Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer

scientific article published on 01 May 1997

Hydroxyl radical production and DNA damage induced by anthracycline-iron complex

scientific article published on 01 July 1984

Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial.

scientific article published on 19 September 2015

Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors

scientific article

Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level

scientific article published on February 2004

Integrative population pharmacokinetic and pharmacodynamic dose finding approach of the new camptothecin compound namitecan (ST1968).

scientific article

International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010).

scientific article published on January 2011

International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations

scientific article

Introducing new molecular technologies into routine clinical cancer care: is there an impact on the treatment of breast cancer?

scientific article published on 01 September 2008

Is there room for another HER2-targeting drug?

scientific article published on 24 May 2018

Ixabepilone and the narrow path to developing new cytotoxic drugs

scientific article published on 02 July 2007

Learning from Cl-941 about pharmacokinetically guided dose escalation

scientific article published on January 1, 1992

Long-term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ-cell tumours

scientific article

Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial

scientific article published on 15 April 2013

Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers.

scientific article published on 30 August 2010

Monoclonal antibodies against doxorubicin

scientific article published in November 1988

Multidrug regimens for treatment of older patients with metastatic pancreatic cancer

scientific article published on 03 July 2020

Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial

scientific article published on 07 July 2018

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort

scientific article published on 20 March 2014

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall

scientific article published in January 2010

Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study

scientific article

Never use anthracyclines with trastuzumab: it is time to reconsider the taboo

scientific article published on 23 April 2009

Omega-3 Fatty Acids for Aromatase Inhibitor-Induced Musculoskeletal Pain: Anything Other Than a Placebo Effect?

scientific article published on 21 September 2015

Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative me

scientific article

Oxidative destruction of DNA by the adriamycin-iron complex.

scientific article published in February 1984

Oxidative destruction of erythrocyte ghost membranes catalyzed by the doxorubicin-iron complex

scientific article published on 01 April 1982

PD-1 Inhibitors-Related Neurological Toxicities in Patients with Non-Small-Cell Lung Cancer: A Literature Review

article

Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: implications for cardiotoxicity of doxorubicin-taxane chemotherapies

scientific article published on 13 April 2006

Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.

scientific article published on November 1995

Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines.

scientific article published on August 1995

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

scientific article published on 14 February 2014

Pathological complete response in breast cancer--authors' reply

scientific article

Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer.

scientific article

Pharmacology and Clinical Toxicity of 4'-Iodo-4'-deoxydoxorubicin: An Example of Successful Application of Pharmacokinetics to Dose Escalation in Phase I Trials

article

Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma.

scientific article published on 12 July 2016

Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors

scientific article published on 6 June 2014

Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors

scientific article published on 07 March 2013

Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer.

scientific article

Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing

scientific article

Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule

scientific article published on 01 September 2007

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

scientific article

Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours.

scientific article published on 17 July 2008

Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas.

scientific article published in February 2018

Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer

scientific article published on 25 November 2010

Phase I/II study of gemcitabine in association with vinorelbine for metastatic breast cancer.

scientific article

Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin.

scientific article published in March 2004

Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.

scientific article published on 20 September 2010

Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer

scientific article published in August 2009

Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy

scientific article published on February 2010

Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer.

scientific article published on 30 March 2009

Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer

scientific article

Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer

scientific article published on 01 December 2003

Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease

scientific article published on February 2008

Primary chemotherapy followed by anterior craniofacial resection and radiotherapy for paranasal cancer.

scientific article published in March 2003

Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer

scientific article published on 19 October 2010

Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers

scientific article published on January 2013

Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer

scientific article

Report on the international colloquium on cardio-oncology (rome, 12-14 march 2014)

scientific article

Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

article

Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables.

scientific article

Role of anthracyclines in the treatment of early breast cancer

scientific article published on 17 August 2009

Role of daunosamine and hydroxyacetyl side chain in reaction with iron and lipid peroxidation by anthracyclines.

scientific article published in September 1988

Role of dose in the treatment of breast cancer.

scientific article published in January 2004

Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial

scientific article

Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study

scientific article published on 03 November 2018

Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma.

scientific article published on 31 August 2017

Seminars in clinical pharmacology: an introduction to MET inhibitors for the medical oncologist.

scientific article published on 30 October 2012

Sequence dependence of the antitumor and toxic effects of 5-fluorouracil and cis-diamminedichloroplatinum combination on primary colon tumors in mice ⬇️

scientific article published on January 1, 1988

Stereoselectivity of iododoxorubicin reduction in various animal species and humans

scientific article published on 01 February 1993

Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection

scientific article published on 13 February 2018

Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer.

scientific article

Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.

scientific article published on 16 August 2011

Surrogate markers for targeted therapy-based treatment activity and efficacy.

scientific article

Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine

scientific article

Targeting TRAIL agonistic receptors for cancer therapy.

scientific article published on April 2007

Targeting the epidermal growth factor receptor a new strategy in cancer treatment.

scientific article

Technology insight: Emerging techniques to predict response to preoperative chemotherapy in breast cancer

scientific article

The "other" signaling of trastuzumab: antibodies are immunocompetent drugs

scientific article published on 17 March 2008

The choice of the correct imaging modality in breast cancer management

scientific article published on 4 May 2004

The cost of life: should it matter to doctors?

scientific article published on 01 March 2006

The future of targeted therapy: combining novel agents

scientific article

The immune system and response to HER2-targeted treatment in breast cancer

scientific article published on February 2014

Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma

scientific article published on 10 March 2020

Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.

scientific article

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

scientific article

Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer

scientific article published on 23 December 2008

Trastuzumab emtansine for HER2-positive advanced breast cancer

scientific article

Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial

scientific article

Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience

scientific article published on 26 December 2015

Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01).

scientific article

Treatment of HER2-positive breast cancer: current status and future perspectives.

scientific article

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

scientific article published on 25 February 2011

Triple-negative breast cancer: an unmet medical need

scientific article

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

scientific article

Triple-negative breast cancer: disease entity or title of convenience?

scientific article published on 28 September 2010

Use of formalin-fixed paraffin-embedded samples for gene expression studies in breast cancer patients

scientific article

Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer

scientific article (publication date: April 2009)

Paulina is supported by:

About Paulina

Help